As of 2026-04-16, the Relative Valuation of Oncopeptides AB (ONCO.ST) is (20.59) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 1.46 SEK, the upside of Oncopeptides AB based on Relative Valuation is -1509.5%.
The range of the Relative Valuation is (18.53) - (23.55) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.8x - 40.6x | 34.6x |
| Forward P/E multiples | 23.3x - 36.6x | 29.4x |
| Fair Price | (18.53) - (23.55) | (20.59) |
| Upside | -1368.5% - -1712.1% | -1509.5% |
| Date | P/E |
| 2026-04-10 | -2.14 |
| 2026-04-09 | -2.12 |
| 2026-04-08 | -2.17 |
| 2026-04-07 | -2.08 |
| 2026-04-02 | -2.18 |
| 2026-04-01 | -2.28 |
| 2026-03-31 | -2.20 |
| 2026-03-30 | -2.18 |
| 2026-03-27 | -2.15 |
| 2026-03-26 | -2.28 |
| 2026-03-25 | -2.23 |
| 2026-03-24 | -2.34 |
| 2026-03-23 | -2.31 |
| 2026-03-20 | -2.32 |
| 2026-03-19 | -2.35 |
| 2026-03-18 | -2.38 |
| 2026-03-17 | -2.63 |
| 2026-03-16 | -2.41 |
| 2026-03-13 | -2.41 |
| 2026-03-12 | -2.60 |
| 2026-03-11 | -2.45 |
| 2026-03-10 | -2.45 |
| 2026-03-09 | -2.45 |
| 2026-03-06 | -2.46 |
| 2026-03-05 | -2.46 |
| 2026-03-04 | -2.50 |
| 2026-03-03 | -2.51 |
| 2026-03-02 | -2.52 |
| 2026-02-27 | -2.64 |
| 2026-02-26 | -2.77 |
| 2026-02-25 | -2.79 |
| 2026-02-24 | -2.74 |
| 2026-02-23 | -2.70 |
| 2026-02-20 | -2.89 |
| 2026-02-19 | -2.64 |
| 2026-02-18 | -4.27 |
| 2026-02-17 | -4.34 |
| 2026-02-16 | -4.42 |
| 2026-02-13 | -4.63 |
| 2026-02-12 | -4.21 |
| 2026-02-11 | -4.30 |
| 2026-02-10 | -4.40 |
| 2026-02-09 | -4.27 |
| 2026-02-06 | -4.30 |
| 2026-02-05 | -4.20 |
| 2026-02-04 | -4.45 |
| 2026-02-03 | -4.63 |
| 2026-02-02 | -4.51 |
| 2026-01-30 | -4.57 |
| 2026-01-29 | -4.62 |